<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04911049</url>
  </required_header>
  <id_info>
    <org_study_id>APHP201318</org_study_id>
    <nct_id>NCT04911049</nct_id>
  </id_info>
  <brief_title>Prevalence and Pathophysiology of Systemic Arterial Pressure Abnormalities in Childhood Sickle Cell Disease</brief_title>
  <acronym>DrépaPA</acronym>
  <official_title>Prevalence and Pathophysiology of Systemic Arterial Pressure Abnormalities in Childhood Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is usually found that the blood pressure of adults with sickle cell disease is lower than&#xD;
      in non-sickle cell patients. On the other hand, three recent prospective studies in children&#xD;
      with sickle cell disease show prevalence of hypertension diagnosed by ambulatory blood&#xD;
      pressure measurement (ABPM) ranging from 32 to 45% but on small numbers of patients (n = 54&#xD;
      at most). This hypertension appears to affect kidney function and has been previously&#xD;
      associated with the risk of hemorrhagic stroke. It is therefore important to know the&#xD;
      prevalence of hypertension in children with sickle cell disease and to determine its&#xD;
      mechanisms. The factors which could explain this high prevalence are the increase in arterial&#xD;
      stiffness and the increase in systemic vascular resistance linked to the alteration of the&#xD;
      sympathovagal balance contributing to the regulation of vascular tone. Indeed, a disturbance&#xD;
      of this balance with an increase in vasoconstrictor sympathetic tone has already been found.&#xD;
      Hypothesis: In a subgroup of sickle cell children there is systemic hypertension (prevalence:&#xD;
      main objective) linked to the alteration of the sympathovagal balance already established&#xD;
      during sickle cell disease (increase in sympathetic tone and decrease in parasympathetic&#xD;
      tone) affecting systemic vascular resistance (secondary pathophysiological objectives).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main objective (200 children): To evaluate the prevalence of elevated blood pressure (former&#xD;
      pre-hypertension) and hypertension (including masked hypertension) in children with sickle&#xD;
      cell disease. Secondary objectives (60 children): to evaluate the prevalence of loss of&#xD;
      nocturnal decrease in blood pressure (dipping); to evaluate arterial stiffness (pulse wave&#xD;
      velocity: PWV) and vascular resistance (Augmentation Index, AI) in the different groups:&#xD;
      normal, pre-hypertension and hypertension; to evaluate the cardiac sympathovagal balance by&#xD;
      studying heart rate variability (HRV) in the three groups: normal, pre-hypertension and&#xD;
      hypertension; to evaluate arterial in the three groups: normal, pre-hypertension and&#xD;
      hypertension; to evaluate whether the absence of nocturnal dipping is or is not an associated&#xD;
      factor of abnormal arterial stiffness, systemic vascular resistance, sympathovagal balance or&#xD;
      baroreflex by comparison of subjects with normal dipping versus abnormal dipping.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Ambulatory Blood Pressure Monitoring (ABPM)</measure>
    <time_frame>2 years</time_frame>
    <description>mean, systolic and diastolic arterial pressure</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Sickle Cell Disease</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood Pressure measurement</intervention_name>
    <description>Blood Pressure measurement</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        childhood sickle cell disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  child (age &lt;18 years);&#xD;
&#xD;
          -  sub-Saharan or Caribbean origin;&#xD;
&#xD;
          -  major sickle cell disease (SS, SC and Sbeta-thalassemia);&#xD;
&#xD;
          -  height ≥ 120 cm; absence of treated hypertension or antihypertensive treatment;&#xD;
&#xD;
          -  parents informed and not opposed to participation in research&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bérengère KOEHL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christophe DELCLAUX, MD, PhD</last_name>
    <phone>+331 40 03 41 90</phone>
    <email>christophe.delclaux@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bérengère KOEHL, MD</last_name>
    <email>berengere.koehl@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Robert Debre Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Delclaux, MD PhD</last_name>
      <phone>+33 1 40 03 41 90</phone>
      <email>christophe.declaux@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sickle cell disease</keyword>
  <keyword>systemic hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

